Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Inspira Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) announces a strategic investment by Mr. Ronen Juster and Ms. Margi Ben-Noon. The company will issue 1,339,285 ordinary shares at $1.232 per share in a registered direct offering.
  • None.
  • None.

The recent strategic investment in Inspira Technologies by a leading investor and the CEO's mother represents a bolstering of confidence in the company's direction and potential. The sale of over 1.3 million shares at a price of $1.232 each suggests a calculated infusion of capital, likely aimed at driving forward the company's initiatives. This move could indicate underlying strength or a need for cash that might not be immediately evident from the company's balance sheet.

Investors should consider the implications of insider investments, as they often signal a belief in the company's future success. However, it is also essential to assess the liquidity position and the potential dilution of existing shares. The injection of funds may serve to accelerate growth or mitigate short-term cash flow issues, yet it also expands the shareholder base, potentially impacting the stock's volatility and future earnings per share.

From a market perspective, Inspira Technologies' strategic investment news can be interpreted as a positive signal to the market, potentially influencing investor sentiment. It is important to understand the context within which this investment occurs, including the company's market position, competitive landscape and growth trajectory. The healthcare technology sector is highly competitive and companies like Inspira must continually innovate and secure capital to stay ahead.

Moreover, the specific price point of the shares could reflect current market valuation and investor appetite for risk in this sector. If the price is perceived as favorable, it could attract additional investors, but if it's seen as a discount due to company struggles, it might raise concerns about the company's valuation and future prospects.

For stakeholders in the healthcare industry, the strategic investment in Inspira Technologies should be evaluated against the backdrop of the company's product pipeline and regulatory environment. The capital raised could be earmarked for research and development, scaling production, or navigating the complex regulatory pathways necessary for bringing medical technologies to market.

Understanding the company's technology and its potential impact on healthcare delivery is critical. If Inspira's offerings are poised to address significant unmet medical needs or introduce efficiencies in healthcare systems, the investment could be seen as a precursor to substantial growth. Conversely, if the company faces significant hurdles in technology adoption or regulatory approval, the investment might be a lifeline rather than an accelerator.

RA'ANANA, Israel, April 1, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), today announced a strategic investment by leading investor, Mr. Ronen Juster, and the mother of Inspira's Chief Executive Officer, Ms. Margi Ben-Noon. The Company has entered into a definitive agreement for the issuance and sale of an aggregate of 1,339,285 of ordinary shares at a price per share of $1.232, in a registered direct offering. The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions.

The proceeds to Inspira from the offering are expected to be $1.65 million Inspira currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No. 333-266748), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 10, 2022, and declared effective by the SEC on August 18, 2022. The offering of such securities is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is leading the way in transforming life-support care. Its innovative solutions are paving the way for direct blood oxygenation, bypassing the lungs, and potentially reducing the need for traditional mechanical ventilation. Beyond this, the Company is committed to advancing blood circulation technology and incorporating AI-driven monitoring systems. These advancements are part of its strategy to offer more patient-focused, data-informed care. The integration of these technologies signifies the potential to enhance patient outcomes and streamline hospital operations, marking a new era in respiratory care.

For more information, please visit our corporate website:

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements under U.S. Federal securities laws. These forward-looking statements and their implications are based only on the current expectations of the management of the Company. They are subject to several factors and uncertainties that could cause results to differ materially from those described in the forward-looking statements, such as market and other conditions. For example, the Company uses forward-looking statements when it discusses the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC, which is available on the SEC's website,

For more details:

Public Relations Manager

Adi Shmueli
Inspira Technologies

Logo -

Inspira Technologies Logo

Cision View original content:

SOURCE Inspira Technologies

The ticker symbols are IINN and IINNW.

Mr. Ronen Juster and Ms. Margi Ben-Noon made a strategic investment.

Inspira will issue 1,339,285 ordinary shares.

The shares will be issued at a price of $1.232 per share.

Inspira is conducting a registered direct offering.
Inspira Technologies Oxy B.H.N. Ltd


IINN Rankings

IINN Latest News

IINN Stock Data

Surgical and Medical Instrument Manufacturing

About IINN

insense medical develops state of the art respiratory support technology as an alternative to mechanical ventilation by 2020 more than 600,000 patients in the u.s. will require mechanical ventilation. 5.7 million patients are admitted annually to icu's with 35% needing ventilation. cost of treatment is estimated at 64 bn$/y as mortality reaches 40%. imagine that instead of mechanical ventilation, or ecmo treatment, a small and safe apparatus is placed into a vein, replacing necessary lung functions without the devastating complications associated with mechanical ventilation. oxylink, an advanced nano vesicle technology. our revolutionary intravascular oxygenation apparatus, safely increases the level of oxygen & reduces the carbon dioxide in blood, enabling your physician to address the primary ventilatory condition.